drugset
drugset / Trial / NCT04006353

The Drug Interaction Between Albuvirtide (ABT) and Rifampin（RIF） in Healthy Adult Subjects

NCT04006353 ↗

Phase 4 Completed 24 enrolled Shanghai Public Health Clinical Center
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to estimate the drug interaction between RIF and ABT. This will be a single-center, open-label, parallel study in healthy adult subjects.

Timeline

Start
2019-07-11
Primary completion
2019-09-30
Completion
2019-12-03

Drugs

EvaluationDrugModalityDoseRoute
Subject ABT Unknown 320 mg Intravenous
Subject RIF Unknown 600 mg —

Indications

No indication recorded.